Page last updated: 2024-11-04

terazosin and Bladder Neck Obstruction

terazosin has been researched along with Bladder Neck Obstruction in 22 studies

Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia

Research Excerpts

ExcerptRelevanceReference
"We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)."9.08Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996)
"To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)."9.08Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998)
"The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old."9.06A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990)
"The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms."7.72Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003)
"To investigate the effectiveness of terazosin, an alpha1-adrenoceptor blocking agent, on bladder neck obstruction (BNO), by assessing the urodynamic hydraulic energy profile."7.70The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. ( Hattori, T; Sakakibara, R; Tojo, M; Yamanishi, T; Yasuda, K, 2000)
"Terazosin treatment, even 2 mg."5.31Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002)
"We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)."5.08Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996)
"To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)."5.08Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998)
"The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old."5.06A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990)
"The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms."3.72Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003)
"To investigate the effectiveness of terazosin, an alpha1-adrenoceptor blocking agent, on bladder neck obstruction (BNO), by assessing the urodynamic hydraulic energy profile."3.70The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. ( Hattori, T; Sakakibara, R; Tojo, M; Yamanishi, T; Yasuda, K, 2000)
"Terazosin was initiated at 1 mg daily and gradually increased to the maintenance dose of 5 mg daily during 2 weeks."2.72The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. ( Burkhard, FC; Kessler, TM; Studer, UE, 2006)
"Terazosin has proved to be safe and results in significant improvement in bladder emptying in our patients with posterior urethral valves."1.35Role of alpha adrenergic blocker in the management of posterior urethral valves. ( Abraham, MK; Damisetti, KR; Kedari, PM; Narayanan, T; Nasir, AR; Puzhankara, R; Sudarsanan, B; Unnithan, GR, 2009)
"Terazosin treatment, even 2 mg."1.31Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002)
"In patients without bladder outlet obstruction (BOO), improvement in maximum flow and symptom scores with little change in the degree of obstruction was most apparent, whereas a decrease of detrusor pressure at maximum flow was observed mainly in patients with BOO."1.30Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. ( de la Rosette, JJ; Debruyne, FM; Neal, DE; Robertson, A; Rosier, PF; Witjes, WP, 1997)
"Functional bladder neck obstruction has been definitively diagnosed in the last few years due to detailed synchronous pressure flow, electromyography and video urodynamics."1.30Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision. ( Gogoi, S; Kumar, A; Mandhani, A; Srivastava, A, 1999)
" The dosage was gradually increased to 1-2 mg twice daily, depending upon patient tolerance and a minimum acceptable systolic blood pressure of 90 mm Hg."1.29Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. ( Perkash, I, 1995)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's11 (50.00)18.2507
2000's10 (45.45)29.6817
2010's1 (4.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abraham, MK1
Nasir, AR1
Sudarsanan, B1
Puzhankara, R1
Kedari, PM1
Unnithan, GR1
Damisetti, KR1
Narayanan, T1
Van Batavia, JP1
Combs, AJ1
Horowitz, M1
Glassberg, KI1
Mudiyala, R1
Ahmed, A1
Kyprianou, N1
Velasco, C1
Guarneri, L1
Leonardi, A1
Testa, R1
Kessler, TM1
Studer, UE1
Burkhard, FC1
Stockamp, K1
Chancellor, MB1
Erhard, MJ1
Rivas, DA1
Perkash, I1
Witjes, WP3
Rosier, FW1
de Wildt, MJ1
van Iersel, MP1
Debruyne, FM3
de La Rosette, JJ4
Rosier, PF2
Caris, CT1
Lepor, H2
Nieder, A1
Feser, J1
O'Connell, C1
Dixon, C1
Robertson, A1
Neal, DE1
Na, YJ1
Guo, YL1
Gu, FL1
Kumar, A1
Mandhani, A1
Gogoi, S1
Srivastava, A1
Yamanishi, T1
Yasuda, K1
Sakakibara, R1
Hattori, T1
Tojo, M1
Caprino, L1
Rossi, C1
Kortmann, BB1
Sonke, GS1
Floratos, DL1
Kiemeney, LA1
Wijkstra, H1
Gu, BJ1
Ishizuka, O1
Igawa, Y1
Nishizawa, O1
Andersson, KE1
Tanaka, Y1
Masumori, N1
Itoh, N1
Sato, Y1
Takahashi, A1
Ogura, H1
Furuya, S1
Tsukamoto, T1
Knapp-Maloney, G1
Sunshine, H1

Reviews

4 reviews available for terazosin and Bladder Neck Obstruction

ArticleYear
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    The Journal of urology, 2003, Volume: 169, Issue:4

    Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hype

2003
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Der Urologe. Ausg. A, 1995, Volume: 34, Issue:1

    Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, A

1995
[New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
    Wiener klinische Wochenschrift, 1995, Volume: 107, Issue:15

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Dose-Response Relationship, D

1995
[Drugs for the treatment of benign prostatic hypertrophy].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2000, Volume: 52, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; D

2000

Trials

6 trials available for terazosin and Bladder Neck Obstruction

ArticleYear
The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.
    The Journal of urology, 2006, Volume: 176, Issue:4 Pt 1

    Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Middle Aged; Pilot Projects; Prazosin; Prospect

2006
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    The Journal of urology, 1996, Volume: 155, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin

1996
Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Urology, 1997, Volume: 49, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prospect

1997
Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
    Urology, 1997, Volume: 49, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prosta

1997
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Journal of medicine, 1998, Volume: 29, Issue:5-6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Dose-Response Relations

1998
A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    The Journal of urology, 1990, Volume: 144, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Administration Schedule; Humans; Male; Midd

1990

Other Studies

12 other studies available for terazosin and Bladder Neck Obstruction

ArticleYear
Role of alpha adrenergic blocker in the management of posterior urethral valves.
    Pediatric surgery international, 2009, Volume: 25, Issue:12

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Child, Preschool; Cystoscopy; Dose-Response Rela

2009
Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy.
    The Journal of urology, 2010, Volume: 183, Issue:2

    Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Female; Humans; Male; Prazosin; S

2010
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin

2003
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
    BJU international, 2003, Volume: 92, Issue:1

    Topics: Administration, Intravesical; Adrenergic alpha-Antagonists; Animals; Female; Infusions, Intravenous;

2003
Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function.
    The Journal of the American Paraplegia Society, 1993, Volume: 16, Issue:4

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Follow-Up Studies; Humans; Male; Middle Aged; Penil

1993
Efficacy and safety of terazosin to improve voiding in spinal cord injury patients.
    The journal of spinal cord medicine, 1995, Volume: 18, Issue:4

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; H

1995
Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
    Urology, 1997, Volume: 50, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Laser Therapy; Male; Microwaves; Middle Aged; Prazosin;

1997
Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision.
    The Journal of urology, 1999, Volume: 162, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Combined Modality Therapy; Equipment Design; Female; Huma

1999
The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy.
    BJU international, 2000, Volume: 85, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pra

2000
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
    The Journal of urology, 2001, Volume: 165, Issue:1

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Prazosin; Quinazolines; Severity of Illness

2001
Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
    The Journal of urology, 2002, Volume: 167, Issue:4

    Topics: Adrenergic alpha-Antagonists; Animals; Consciousness; Female; Injections, Intraventricular; Prazosin

2002
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    The Journal of urology, 2002, Volume: 167, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Japan; Male; Middle Aged; Muscle Cont

2002